C1S (Claseprubart Biosimilar) Recombinant Monoclonal Antibody

Code CSB-RA003657MB2HU
Size US$9799
Order now
Have Questions? Leave a Message or Start an on-line Chat

Product Details

Uniprot No.
Target Names
Alternative Names
DNTH103 research-grade biosimilar; DNTH 103 research-grade biosimilar; DNTH-103 research-grade biosimilar; TX301 research-grade biosimilar; ZB-005 research-grade biosimilar ;C1S antibody; Complement C1s subcomponent antibody; EC 3.4.21.42 antibody; C1 esterase antibody; Complement component 1 subcomponent s [Cleaved into: Complement C1s subcomponent heavy chain antibody; Complement C1s subcomponent chain A antibody; Complement C1s subcomponent light chain antibody; Complement C1s subcomponent chain B] antibody
Species Reactivity
Human
Immunogen
Recombinant Human C1S protein
Immunogen Species
Homo sapiens (Human)
Conjugate
Non-conjugated
Clonality
Monoclonal
Concentration
It differs from different batches. Please contact us to confirm it.
Buffer
0.01M PBS,pH7.4
Form
Liquid
Troubleshooting and FAQs
Storage
Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
Notes
Validation Status
Application-specific performance (e.g., in flow cytometry, ELISA, IHC or other assay formats) has not yet been experimentally verified by CUSABIO. Users are advised to determine the optimal working conditions empirically in their own assay systems.
Guaranteed Quality
① Antibody purity > 95% tested by SDS-PAGE.
② Endotoxin level < 0.1EU/ug tested by LAL method.
Lead Time
3-4 weeks
Description

This recombinant monoclonal antibody is a research-grade biosimilar to Claseprubart, designed for research applications targeting complement component 1s (C1S). C1S is a serine protease that functions as part of the C1 complex in the classical complement pathway, where it cleaves complement components C2 and C4 to initiate the complement cascade. This proteolytic activity plays a critical role in immune defense, but dysregulated C1S activation contributes to various pathological conditions including autoimmune diseases, antibody-mediated rejection in transplantation, and complement-mediated inflammatory disorders. Aberrant complement activation has been implicated in conditions such as cold agglutinin disease and other complement-driven hemolytic anemias.

Claseprubart is a therapeutic antibody developed to selectively inhibit C1S activity, thereby modulating classical complement pathway activation. This biosimilar provides researchers with a valuable tool for investigating C1S-mediated mechanisms in complement biology, exploring the role of classical pathway activation in disease models, and evaluating potential therapeutic strategies for complement-related disorders. It enables detailed studies of complement regulation and immune-mediated pathologies in controlled laboratory settings.

Usage
It is a non-therapeutic biosimilar antibody, owning the same variable region from the corresponding approved therapeutic antibody. In conclusion, it is a research-grade biosimilar antibody and expressed in mammalian cell, which can be directly used as positive controls in drug discovery or used for rapid verification of the biological functions of target protein.

Customer Reviews and Q&A

 Customer Reviews

There are currently no reviews for this product.

Submit a Review here

Target Background

Function
C1s B chain is a serine protease that combines with C1q and C1r to form C1, the first component of the classical pathway of the complement system. C1r activates C1s so that it can, in turn, activate C2 and C4.
Gene References into Functions
  1. TNT003, an inhibitor of the serine protease C1s, prevents complement activation induced by cold agglutinins. PMID: 24695853
  2. Data indicate that complement C1s mRNA level was low in ICR-derived glomerulonephritis (ICGN) mice liver as compared with age-matched ICR mice. PMID: 23989031
  3. A molecular switch governs the interaction between the human complement protease C1s and its substrate, complement C4. PMID: 23592783
  4. Four positively charged amino acids on the serine protease domain appear to form a catalytic exosite that is required for efficient cleavage of C4 in the classical pathway of complement. PMID: 22855709
  5. Detailed mapping of post-translational modifications and insights into the C1r/C1s binding sites. PMID: 20008834
  6. Interaction with the prime side residues at the cleavage point in C1s enhances the affinity of the enzyme for complement 2 and complement 4 substrates; these prime subsite residues mediate positive cooperativity in the cleavage of the substrate. PMID: 14674770
  7. full specificity of the enzyme using a randomized phage display library PMID: 16169853
  8. There are splice variants of C1s mRNA transcripts in normal human cells PMID: 18062908

Show More

Hide All

Involvement in disease
Complement component C1s deficiency (C1SD); Ehlers-Danlos syndrome, periodontal type, 2 (EDSPD2)
Protein Families
Peptidase S1 family
Database Links

HGNC: 1247

OMIM: 120580

KEGG: hsa:716

STRING: 9606.ENSP00000328173

UniGene: Hs.458355

icon of phone
Call us
301-363-4651 (Available 9 a.m. to 5 p.m. CST from Monday to Friday)
icon of address
Address
7505 Fannin St., Ste 610, Room 7 (CUBIO Innovation Center), Houston, TX 77054, USA
icon of social media
Join us with

Subscribe newsletter

Leave a message

* To protect against spam, please pass the CAPTCHA test below.
CAPTCHA verification
© 2007-2026 CUSABIO TECHNOLOGY LLC All rights reserved. 鄂ICP备15011166号-1
Place an order now

I. Product details

*
*
*
*

II. Contact details

*
*

III. Ship To

*
*
*
*
*
*
*

IV. Bill To

*
*
*
*
*
*
*
*